IONIS GSK4LRx

Drug Profile

IONIS GSK4LRx

Alternative Names: IONISGSK4LRx; ISIS-GSK4-LRx; ISIS-GSK4Rx

Latest Information Update: 24 Dec 2015

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Developer GlaxoSmithKline
  • Class Antisense oligonucleotides; Eye disorder therapies
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Eye disorders

Most Recent Events

  • 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
  • 26 Oct 2015 Phase-I clinical trials in Eye disorders (In volunteers) in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top